“…This has already been proposed for the treatment of both hepatitis C (He et al, 2015) and Ebola virus (Sakurai et al, 2015) infections. Heparin, the widely used anticoagulant, has potentially attractive features including activity against attachment and entry of the enveloped viruses, human simplex (HSV) (Herold et al, 1996;Nahmias and Kibrick, 1964), human immunodeficiency (HIV) (Baba et al, 1988), SARS coronavirus (Vicenzi et al, 2004), and influenza (H5N1) . Here, we explore the effects of heparin on ZIKV infection in human neural progenitor cells (hNPCs) with particular regard to virus replication and induction of cytopathic effects (CPE) resulting in cell death.…”